Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor

被引：0
|
作者：
Zhong, Helen
Xiong, Yan
Huang, Han
Pan, Yuming
Cao, Lijin
Liu, Shen
Wang, Na
Sun, Bing
Liu, Dingguo
Yuan, Wei
Fang, Jan
Bao, Haifeng
机构：
[1] BiOneCure Therapeut, Germantown, MD USA
[2] BiOneCure Therapeut LLC, Germantown, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15013
引用
收藏
页数：1
相关论文
共 50 条
  • [31] DS-3939a, a novel TA-MUC1-targeting antibody-drug conjugate (ADC) with a DNA topoisomerase I inhibitor DXd, exhibits potent antitumor activity in preclinical models
    Yukiura, Mayuko
    Takano, Kohei
    Takahashi, Kazuki
    Zembutsu, Akiko
    Kitamura, Michiko
    Shiose, Yoshinobu
    Honda, Kokichi
    Oyama, Kazunori
    Obuchi, Wataru
    Yamada, Makiko
    Goto, Riki
    Sakurai, Ken
    Kumagai, Kazuyoshi
    Kagari, Takashi
    Abe, Yuki
    Agatsuma, Toshinori
    CANCER RESEARCH, 2024, 84 (06)
  • [32] Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan
    Goldenberg, David M.
    Sharkey, Robert M.
    MABS, 2019, 11 (06) : 987 - 995
  • [33] An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index
    Hui, Xiwu
    Yuan, Can
    Cao, Weirong
    Ge, Wenli
    Zhang, Di
    Dan, Mo
    Zhao, Qian
    Liu, Boning
    Yao, Bing
    ONCOTARGETS AND THERAPY, 2022, 15 : 331 - 343
  • [34] Targeting HER2-positive brain metastases by incorporating the brain penetrant Angiopep-2 peptide to an anti-HER2 antibody and anti-HER2 antibody drug conjugate
    Demeule, Michel
    Das, Sanjoy
    Che, Christian
    Yang, Gaoqiang
    Currie, Jean-Christophe
    Lord-Dufour, Simon
    Tripathy, Sasmita
    Regina, Anthony
    Castaigne, Jean-Paul
    Lachowicz, Jean E.
    CANCER RESEARCH, 2015, 75
  • [35] Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors
    Xu, Jian
    Zong, Qing
    Zhu, Liang
    Liu, Qigang
    Stann, Sasha
    Cai, Jiaqiang
    CANCER RESEARCH, 2023, 83 (07)
  • [36] Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors
    Ma, Dangshe
    Narayanan, Bitha
    Marquette, Kim
    Graziani, Edmund
    Loganzo, Frank
    Charati, Manoj
    Prashad, Nadira
    Tumey, Nathan
    Golas, Jon
    Hosselet, Christine
    Hu, George
    Barletta, Frank
    Betts, Alison
    Lucas, Judy
    O'Donnell, Chris
    Tchistiakova, Lioudmila
    Gerber, Hans-Peter
    Sapra, Puja
    CANCER RESEARCH, 2016, 76
  • [37] Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer br
    Zhang, Jian
    Ji, Dongmei
    Shen, Weina
    Xiao, Qin
    Gu, Yajia
    'Shaughnessy, Joyce
    Hu, Xichun
    CLINICAL CANCER RESEARCH, 2022, 28 (19) : 4212 - 4221
  • [38] Comparative analysis of anti-HER2 antibody-drug conjugates in tumor spheroid models
    McBain, Kirsty
    Barnes, Kalpana
    Bevan, Nicola
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
    Saleh, Khalil
    Khoury, Rita
    Khalife, Nadine
    Chahine, Claude
    Ibrahim, Rebecca
    Tikriti, Zamzam
    Le Cesne, Axel
    CANCER DRUG RESISTANCE, 2024, 7 : 2 - 15
  • [40] Preclinical data of SYD985 support the clinical investigation of this novel anti-HER2 antibody-drug conjugate in breast cancer patients with low levels of HER2 expression
    Verheijden, Gijs
    Beusker, Patrick
    Ubink, Ruud
    van der Lee, Miranda
    Groothuis, Patrick
    Goedings, Peter
    Egging, David
    Timmers, Marco
    Dokter, Wim
    CANCER RESEARCH, 2015, 75
12345